Search

Displaying results 1651 - 1660 of 7452 in total
  1. Drug

    Technetium Tc-99m red blood cells

    go.drugbank.com/drugs/DB09493
    ApprovedWithdrawn

    Radiolabeled red blood cells are re-injected intravenously into the patient for gamma scintigraphic imaging [FDA Label]. … Technetium Tc-99m red blood cells is a radiopharmaceutical diagnostic agent that is intravenously administered to be used in blood pool imaging, including cardiac first pass and gated equilibrium imaging and for

  2. Drug

    Phenindamine

    go.drugbank.com/drugs/DB01619
    Approved

    Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells.

    Categories: Antihistamines for Systemic Use
  3. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. … [L10926] It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine.

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  4. Drug

    Ajmaline

    go.drugbank.com/drugs/DB01426
    ApprovedWithdrawn

    In these cases, abnormal prolongation of the HV interval has been taken as a proof for infrahisian conduction defects tributary for permanent pacemaker implantation. … It has also been used for many years as a drug to challenge the conduction system of the heart in cases of bundle branch block and syncope.

  5. Drug

    Azelastine

    go.drugbank.com/drugs/DB00972
    ApprovedInvestigational

    Azelastine, a phthalazine derivative, is an antihistamine available as an intranasal spray for the treatment of allergic and vasomotor rhinitis and as an ophthalmic solution for the treatment of allergic … [L8240,L8270] Azelastine is also available in combination with fluticasone propionate as a nasal spray marketed under the trade name Dymista™, which is indicated for the symptomatic treatment of seasonal

    Categories: Antihistamines for Systemic Use
  6. Drug

    Rezafungin

    go.drugbank.com/drugs/DB16310
    ApprovedInvestigational

    [A258403] In March 2023, the FDA approved rezafungin for injection for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options. … [A258398,L45633] Clinical studies have shown that rezafungin is non-inferior to caspofungin for the treatment of candidaemia and invasive candidiasis.

  7. Drug

    Tamoxifen

    go.drugbank.com/drugs/DB00675
    ApprovedInvestigational

    [L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. … [A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.

  8. Drug

    Cantharidin

    go.drugbank.com/drugs/DB12328
    ApprovedInvestigational

    [A32891, A32892] For its natural purpose, the male blister beetle secretes and presents the cantharidin to a female beetle as a copulatory gift during mating. … Available synthetically since the 1950s, topical applications of cantharidin have been used predominantly as a treatment for cutaneous warts since that time.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Afamelanotide

    go.drugbank.com/drugs/DB04931
    Approved

    [L9092] Despite its relatively recent approval, afamelanotide has been available for use as an orphan drug in both the US and EU since 2008.[L9122,L9125] … [L9086] It differs structurally from its endogenous counterpart by only two amino acids - these structural differences improve biological efficacy by imparting a greater affinity for its target and a longer

    Categories: Protectives Against UV-Radiation for Systemic Use, Compounds used in a research, industrial, or household setting
  10. Drug

    Patisiran

    go.drugbank.com/drugs/DB14582
    Approved

    It is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].

    Categories: Compounds used in a research, industrial, or household setting